1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Ireland Pharmaceuticals and Healthcare Report Q1 2017

Ireland Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 76 pages

Includes 3 FREE quarterly updates


BMI View:

A significant increase in Ireland’s 2017 health budget will support the increasing demand for medical treatment. However, cost control measures targeting pharmaceutical spending and the relatively small drug market will continue to tarnish Ireland’s market appeal to drugmakers. Meanwhile, active support from the Irish government, a skilled workforce and the well-developed export base will ensure that pharmaceutical investment in R&D and manufacturing capacity in Ireland remain robust in the years ahead.

Headline Expenditure Projections



- Pharmaceuticals: EUR2.32bn (USD2.57bn) in 2015 to EUR2.28bn (USD2.44bn) in 2016; -1.8% in local currency terms and -5.3% in US dollar terms. Forecast in line in local currency terms and revised downwards in US dollar terms from last quarter.

- Healthcare: EUR15.09bn (USD16.73bn) in 2015 to EUR15.49bn (USD16.57bn) in 2016; +2.7% in local currency terms and -1.0% in US dollar terms. Forecast in line in local currency terms and revised downwards in US dollar terms from last quarter. In Q117, we have revised upwards Ireland’s Risk Reward Index (RRI) score to 63.0 from 61.0 previously (out of 100). The score revision was driven by higher Industry Rewards indices. Ireland shifted up one ranking position to 13th out of 15 countries in Western Europe in terms of market attractiveness to pharmaceutical investors. Ireland’s score is driven by high spending per capita on medicine and low industry and country risks but is dragged down by a small market size as well as the effects of cost control measures targeting pharmaceutical and health spending.

Table Of Contents

Ireland Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Ireland 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ireland 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ireland 2012-2020) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ireland 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Top 15 Pharmaceuticals and Healthcare Export Companies In 2013 27
Table: Pharmaceutical Trade Data And Forecasts (Ireland 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Ireland 2014-2020) 28
Industry Risk/Reward Index 29
Western Europe Risk/Reward Index 29
Ireland Risk/Reward Index 34
Rewards 34
Risks 35
Regulatory Review 36
Intellectual Property Issues 40
Pricing Regime 41
Reimbursement Regime 43
Market Overview 47
Healthcare Sector 48
Table: Health Status 52
Table: Healthcare Funding 52
Table: Healthcare Resources (Ireland 2010-2015) 53
Table: Healthcare Personnel (Ireland 2010-2015) 53
Table: Healthcare Activity (Ireland 2010-2015) 54
Research and Development 54
Clinical Trials 55
Epidemiology 57
Competitive Landscape 59
Research-Based Industry 59
Table: Multinational Market Activity 61
Table: Pharmaceutical Companies In Ireland 62
Generic Drugmakers 63
Pharmaceutical Distribution 64
Demographic Forecast 65
Table: Population Headline Indicators (Ireland 1990-2025) 66
Table: Key Population Ratios (Ireland 1990-2025) 66
Table: Urban/Rural Population and Life Expectancy (Ireland 1990-2025) 67
Table: Population By Age Group (Ireland 1990-2025) 67
Table: Population By Age Group % (Ireland 1990-2025) 68
Glossary 70
Methodology 72
Pharmaceutical Expenditure Forecast Model 72
Healthcare Expenditure Forecast Model 72
Notes On Methodology 73
Risk/Reward Index Methodology 74
Index Overview 75
Table: Pharmaceutical Risk/Reward Index Indicators 75
Indicator Weightings 76

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.